logo-loader

Genprex reveals slew of recent milestones as it plans for upcoming clinical trials

Published: 17:16 02 Jul 2020 EDT

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner talks to Proactive's Christine Corrado about the Texas-based biotechnology company's most recent updates.

Namely, Varner says the firm has approved the generic name quaratusugene ozeplasmid, for its non-small cell lung cancer drug formerly known as Oncoprex. What's more, its ramping up the production of its drug for upcoming clinical trials, and the company has joined the Russell 3000 index.

Poseidon Nickel signs binding agreement with Mineral Resources to divest...

Departing Poseidon Nickel Ltd (ASX:POS, OTC:PSDNF) CEO Craig Jones and incoming CEO Brendan Shalders join Proactive’s Jonathan Jackson to discuss the divestment of Lake Johnston to Mineral Resources Ltd (ASX:MIN). Jones, who has played a pivotal role in this strategic move, shared insights on...

1 hour, 44 minutes ago